| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| ln Vitro |
The chorioallantoic membrane experiment demonstrates a dependent angiogenesis inhibitory action of oglufanide (IM862) (1-1000 μg/mL), which totally inhibits β-FGF and VEGF-induced angiogenesis [3]. -L-trp) (0-1000 μg/mL; 5 days) failed to affect the viability of HUVEC or tumor cells. [4]
|
|---|---|
| ln Vivo |
Oglufanide (L-glu-L-trp) shows anticancer efficacy in vaccines for immunocompetent and immunodeficient individuals (1–100 mg/kg/day; sc; 10 days) [4].
|
| Animal Protocol |
Animal/Disease Models: C57BL/6 immunocompetent mice, Lewis lung cancer (LLC) xenografts; Balb/C athymic mice, M21 human melanoma xenografts [4] Doses: 1, 10, 50 and 100 mg/ kg/day
Doses: SC, 10 days Experimental Results: Dose-dependent inhibition of LLC tumor growth in syngeneic immunization Xenograft tumor volume in Balb/C athymic mice transplanted with M21 human melanoma cells as a function of dose diminished dependence. |
| References | |
| Additional Infomation |
Glu-Trp is a dipeptide composed of L-glutamate and L-tryptophan linked by peptide bonds. It has multiple functions, including as a metabolite, immunomodulator, angiogenesis regulator, and antitumor agent. Its functions are related to L-glutamate and L-tryptophan.
Oglufanib is a synthetic dipeptide immunomodulator being developed for the treatment of chronic hepatitis C virus infection. Oglufanib was initially developed in Russia (registered as a drug there) for the treatment of serious infectious diseases and underwent extensive cancer clinical trials in the United States before being acquired by Implicit Bioscience in 2005. Oglufanib is administered intranasally as an immunomodulator for the treatment of patients with chronic hepatitis C virus infection. Pharmacodynamics Oglufanib works by modulating the body's inherent immune response to fight invading pathogens and cancer cells. It may control or reverse the immune system suppression utilized by hepatitis viruses, thereby opposing our normal healthy defense mechanisms. |
| Molecular Formula |
C16H19N3O5
|
|---|---|
| Molecular Weight |
333.3392
|
| Exact Mass |
333.132
|
| CAS # |
38101-59-6
|
| PubChem CID |
100094
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
738.9±60.0 °C at 760 mmHg
|
| Flash Point |
400.7±32.9 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.659
|
| LogP |
0.5
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
24
|
| Complexity |
484
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)N
|
| InChi Key |
LLEUXCDZPQOJMY-AAEUAGOBSA-N
|
| InChi Code |
InChI=1S/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/m0/s1
|
| Chemical Name |
(4S)-4-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~15.5 mg/mL (~46.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9999 mL | 14.9997 mL | 29.9994 mL | |
| 5 mM | 0.6000 mL | 2.9999 mL | 5.9999 mL | |
| 10 mM | 0.3000 mL | 1.5000 mL | 2.9999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
